Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental area.
about
Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agentsThe other face of depression, reduced positive affect: the role of catecholamines in causation and cureToward an integrative understanding of social phobiaPreferential modulation of mesolimbic vs. nigrostriatal dopaminergic function by serotonin(2C/2B) receptor agonists: a combined in vivo electrophysiological and microdialysis studyEffects of S-citalopram, citalopram, and R-citalopram on the firing patterns of dopamine neurons in the ventral tegmental area, N-methyl-D-aspartate receptor-mediated transmission in the medial prefrontal cortex and cognitive function in the ratBupropion-induced acute dystonia.Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission.Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data.Metabolic mapping of the effects of the antidepressant fluoxetine on the brains of congenitally helpless rats.Role of serotonin in central dopamine dysfunction.Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function.Fluoxetine, desipramine, and the dual antidepressant milnacipran reduce alcohol self-administration and/or relapse in dependent ratsFluoxetine alleviates behavioral depression while decreasing acetylcholine release in the nucleus accumbens shell.Role of serotonin in cocaine effects in mice with reduced dopamine transporter function.Dopamine, depression and antidepressants.Role of 5-hydroxytryptamine 1B (5-HT1B) receptors in the regulation of ethanol intake in rodents.Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo.Animal models and treatments for addiction and depression co-morbidity.Physiologically relevant changes in serotonin resolved by fast microdialysis.Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues.Critical role of the embryonic mid-hindbrain organizer in the behavioral response to amphetamine and methylphenidate.Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter--a review of current understanding of its mechanism of action.Multiple controls exerted by 5-HT2C receptors upon basal ganglia function: from physiology to pathophysiology.Interaction between the 5-HT system and the basal ganglia: functional implication and therapeutic perspective in Parkinson's disease.Restoration of positive mood states in major depression as a potential drug development target.Antidepressant drug development: Focus on triple monoamine reuptake inhibition.The dopamine D3 receptor, a quarter century later.A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment.Selective genetic disruption of dopaminergic, serotonergic and noradrenergic neurotransmission: insights into motor, emotional and addictive behaviour.Effects of chronic antidepressant drug administration and electroconvulsive shock on activity of dopaminergic neurons in the ventral tegmentumEffects of sustained serotonin reuptake inhibition on the firing of dopamine neurons in the rat ventral tegmental area.Selective serotonin reuptake blockade increases extracellular dopamine in noradrenaline-rich isocortical but not prefrontal areas: dependence on serotonin-1A receptors and independence from noradrenergic innervation.Fluoxetine increases extracellular dopamine in the prefrontal cortex by a mechanism not dependent on serotonin: a comparison with citalopram.Activation of postsynaptic 5-HT(1A) receptors by fluoxetine despite the loss of firing-dependent serotonergic input: electrophysiological and neurochemical studies.Acute dystonic reaction in an elderly patient with mood disorder after titration of paroxetine: possible mechanisms and implications for clinical care.Abnormal temporal difference reward-learning signals in major depression.Dopamine System Dysregulation in Major Depressive Disorders.Role of serotonin(2A) and serotonin(2B/2C) receptor subtypes in the control of accumbal and striatal dopamine release elicited in vivo by dorsal raphe nucleus electrical stimulation.Chronic escitalopram treatment caused dissociative adaptation in serotonin (5-HT) 2C receptor antagonist-induced effects in REM sleep, wake and theta wave activity.Acute and repeated administration of fluoxetine, citalopram, and paroxetine significantly alters the activity of midbrain dopamine neurons in rats: an in vivo electrophysiological study.
P2860
Q28140526-A9B493B1-B294-496D-9BCF-85ED1DE35DE5Q28269179-8B331B76-0D81-478D-A44C-3A5FB4A6EB87Q28366405-AABD9238-DD13-408B-AFCF-660FDDEA14C9Q28377153-63BCB9F6-2979-4791-AC1D-08D026D6AD16Q28571028-174D3013-3DCB-471D-8CA7-540DBEDA04A5Q30308716-6C764D08-BBE2-4081-9036-9E354F18D19AQ30493133-FCDC71CA-46C7-4A1B-A9DF-59C566F5C108Q33488312-A45AE514-3CCF-4CBD-942F-F1DBF228BF61Q33976508-5C579F29-27C8-451B-8B3E-6D2567E64415Q34022787-30E1344D-4D07-4B0F-BB10-498C54735F37Q34273354-929E1E8C-E05E-4FDD-B836-D0B5E8E0708BQ34988454-6BC8217F-0704-4B2E-985B-E098D1E09ED3Q35112122-8103042D-D66A-47D2-AFA7-04BFBB3FB829Q35122959-5BE893C8-7C15-4C0C-9C6E-23E91013E999Q35952682-DBE42B32-1A8D-4A03-ABD4-791E032CDB40Q36481024-FA0BB33D-F8DD-4F15-A917-55E12F50E14DQ36593835-123A0ACC-2693-4A81-A109-BC1AB183E3F4Q36797967-545B0578-96CF-4239-A04C-F77FE827F2BEQ36851690-C944C90A-CE5E-4D75-A360-017195B5E50AQ37252495-49FB29C1-BDA6-4F5A-AB62-DBC9BEA22071Q37439849-B725598F-52A1-4713-8E11-BF44DD5387B7Q37928965-E57B04A5-F93B-414D-85A8-ED4DCA88458EQ38101499-B0D0289F-807E-4789-9D3B-DEFFE16BAFEEQ38199670-D53AD2CB-9E12-4252-8683-78D10CC17667Q38210460-C913CDB4-82A5-4F43-96C5-E67D92752F31Q38260259-38BE63AB-F8FF-46AE-A7F8-D912E58E741DQ38947750-2B623C1E-583D-4C08-B231-AFF4BFFB0AECQ39164871-64358AE9-536F-4F31-9BD2-32DA52AD70CEQ40879980-E9C1B526-92A3-4CB4-959B-DDDDE6A1A43EQ41816897-96FF68D5-017F-45BF-A1AE-BAC38232E693Q42129272-50DF38B5-4B2C-4BCA-8DD5-45776D09925CQ42476634-39092512-C143-4B69-AE16-9DDE4FF793D9Q42476714-01A2EAE9-D749-46AB-8619-FE8D7152DAA2Q42504352-B5443F8E-78E4-4458-9F39-BA24D1877F7BQ44263567-AD34AA8A-3273-45D2-89D5-A6852F4EAC1DQ46519185-31DCEE02-7825-4798-BE6F-7E05C3714ACCQ47123548-B54894A6-0A9B-4C88-964C-7733098BAF66Q48127929-88DCD50E-588B-4B9F-A6D2-626D6D85A8D8Q48133366-E8152E13-2DE1-4FDC-9AD0-B44DB8E8F4A5Q48363477-77AC9817-7991-4BE9-AF34-3ABE0B36D58F
P2860
Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental area.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Differential effects of acute ...... in the ventral tegmental area.
@ast
Differential effects of acute ...... in the ventral tegmental area.
@en
type
label
Differential effects of acute ...... in the ventral tegmental area.
@ast
Differential effects of acute ...... in the ventral tegmental area.
@en
prefLabel
Differential effects of acute ...... in the ventral tegmental area.
@ast
Differential effects of acute ...... in the ventral tegmental area.
@en
P2860
P1476
Differential effects of acute ...... in the ventral tegmental area.
@en
P2093
P2860
P304
P356
10.1111/J.1476-5381.1995.TB16684.X
P407
P577
1995-09-01T00:00:00Z